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AP1S3 Mutations Cause Skin
Autoinflammation by Disrupting
Keratinocyte Autophagy and
Up-Regulating IL-36 Production
Satveer K. Mahil1, Sophie Twelves1, Katalin Farkas2, Niovi Setta-Kaffetzi1, A. David Burden3,
Joanna E. Gach4, Alan D. Irvine5, La´szlo´ Ke´pı´ro´6, Maja Mockenhaupt7, Hazel H. Oon8, Jason Pinner9,
Annamari Ranki10, Marieke M.B. Seyger11, Pere Soler-Palacin12, Eoin R. Storan13, Eugene S. Tan8,
Laurence Valeyrie-Allanore14, Helen S. Young15, Richard C. Trembath1, Siew-Eng Choon16,
Marta Szell2,17, Zsuzsanna Bata-Csorgo2,6, Catherine H. Smith1, Paola Di Meglio18,
Jonathan N. Barker1,19 and Francesca Capon1,19
Prominent skin involvement is a defining characteristic of autoinflammatory disorders caused by abnormal IL-1
signaling. However, the pathways and cell types that drive cutaneous autoinflammatory features remain poorly
understood. We sought to address this issue by investigating the pathogenesis of pustular psoriasis, a model of
autoinflammatory disorders with predominant cutaneous manifestations. We specifically characterized the
impact of mutations affecting AP1S3, a disease gene previously identified by our group and validated here in a
newly ascertained patient resource. We first showed that AP1S3 expression is distinctively elevated in kerati-
nocytes. Because AP1S3 encodes a protein implicated in autophagosome formation, we next investigated the
effects of gene silencing on this pathway. We found that AP1S3 knockout disrupts keratinocyte autophagy,
causing abnormal accumulation of p62, an adaptor protein mediating NF-kB activation. We showed that as a
consequence, AP1S3-deficient cells up-regulate IL-1 signaling and overexpress IL-36a, a cytokine that is
emerging as an important mediator of skin inflammation. These abnormal immune profiles were recapitulated
by pharmacological inhibition of autophagy and verified in patient keratinocytes, where they were reversed by
IL-36 blockade. These findings show that keratinocytes play a key role in skin autoinflammation and identify
autophagy modulation of IL-36 signaling as a therapeutic target.
Journal of Investigative Dermatology (2016) 136, 2251e2259; doi:10.1016/j.jid.2016.06.618
INTRODUCTION
Autoinflammatory disorders (AIDs) are a group of inherited
conditions caused by abnormal activation of the innate
immune system. AIDs typically present with recurrent and
seemingly unprovoked episodes of systemic upset, which
are almost invariably accompanied by joint and skin
inflammation (Aksentijevich and Kastner, 2011). The latter
can manifest with urticarial, pustular, or ulcerative eruptions,
which are considered important markers of disease activity
(Beer et al., 2014).
In the last 15 years, genetic studies have identified more
than 30 AID genes, illuminating fundamental innate immune
pathways and highlighting pathogenic mechanisms (most
notably, abnormal IL-1 production) that have been success-
fully targeted by therapeutic interventions (de Jesus et al.,
2015).
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Despite these successes, the basis of organ-specific disease
manifestations is still unclear. This is particularly true of skin
pathology, because the nature of the cells and molecular
mechanisms that mediate cutaneous inflammation in AID
remain poorly defined (Beer et al., 2014).
We sought to address this issue by investigating the path-
ogenesis of pustular psoriasis, a severe AID manifesting with
repeated eruptions of painful skin pustules. These can be
localized to the palms and soles (palmar plantar pustulosis),
toes and fingertips (acrodermatitis continua of Hallopeau) or
affect most of the body surface (generalized pustular psoria-
sis). Although the lesions can be accompanied by arthritis
and systemic upset, cutaneous involvement is the most
prominent clinical feature of the disease (Griffiths and Barker,
2010). This makes pustular psoriasis an ideal model for
investigating the molecular mechanisms that drive skin
inflammation in AID.
We specifically investigated the pathogenic role of AP1S3,
a gene that we found to be mutated in all forms of pustular
psoriasis (Setta-Kaffetzi et al., 2014). AP1S3 encodes a
subunit of AP-1, a heterotetramer that mediates membrane
trafficking between the post-Golgi network and the endo-
some (Robinson, 2004). The complex is composed of two
large (AP-1g1 and AP-1b1), one medium (AP-1m1) and one
small subunit (AP-1s1). The latter exists in three alternative
forms (AP-1s1A, AP-1s1B and AP-1s1C), encoded by
paralogous genes (AP1S1, AP1S2, AP1S3), so that the AP1S3
product is AP-1s1C (Figure 1a). The s1 subunit confers
stability to AP-1 tetramers, so that mutations in AP1S genes
are expected to disrupt the entire complex (Robinson,
2004).
The AP-1 complex has also been implicated in the for-
mation of autophagosomes (Guo et al., 2012). These are
specialized vesicles that mediate the degradation of
cellular components by autophagy, a catabolic process that
can be activated by nutrient stress (e.g., starvation). Given
that autophagy modulates cytokine production down-
stream of various pattern recognition receptors
(Netea-Maier et al., 2016), we hypothesized that AP1S3
mutations would disturb autophagic activity, causing
innate immune dysregulation. We then validated our
pathogenic model in a variety of in vitro experimental
systems and in patient cells.
RESULTS
Validation of AP1S3 as a pustular psoriasis gene
Although we previously reported that two AP1S3 mutations
(p.Phe4Cys and p.Arg33Trp) account for approximately 10%
of European pustular psoriasis patients (Setta-Kaffetzi et al.,
2014), the rarity of the disease has hindered the replication
of this finding. To address this issue, we screened the AP1S3
coding region in 85 newly ascertained patients (53 European
and 32 non-European subjects) (see Supplementary Table S1
online), recruited across Europe and East Asia. This uncov-
ered p.Phe4Cys and p.Arg33Trp alleles in five unrelated
individuals (n ¼ 3 generalized pustular psoriasis and n ¼ 2
palmar plantar pustulosis patients) (Table 1). All were of
European descent, confirming the limited geographic distri-
bution of the two mutations. Two of the three generalized
pustular psoriasis patients carried the AP1S3 mutation in
conjunction with a deleterious change in IL36RN, a pustular
psoriasis gene encoding the IL-36 receptor antagonist
Figure 1. AP1S3 loss-of-function mutations are most likely to affect skin keratinocytes. (a) Schematic representation of AP-1 structure. (b) HEK293 cells were
transfected with wild-type and mutant AP1S3 constructs. Lysates were subjected to the indicated temperature gradient, and soluble (nondenatured) proteins
were analyzed by Western blotting. The densitometry shows the fraction of nondenatured protein (mean  standard error of the mean of the results obtained
in two experiments). (c) HEK293 cells were transfected with myc-tagged AP1S3 and FLAG-tagged AP1M1 constructs. Lysates were subjected to immune
precipitation (IP) and immune blotting (IB) as indicated. The image is representative of results obtained in two experiments. (d) Real-time PCR analysis showing
abundant AP1S3 expression in keratinocytes. The data show the mean  standard error of the mean of measurements obtained in two donors. *P  0.05.
IB, immune blotting; IP, immune precipitation; WCE, whole cell extracts; wt, wild type.
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(Marrakchi et al., 2011; Onoufriadis et al., 2011). One of
these individuals exhibited a particularly severe, recalcitrant
phenotype and had a sister with a milder form of the disease,
who only carried the IL36RN mutation (see Supplementary
Table S2 online).
Taken together, these observations validate the involve-
ment of AP1S3 in pustular psoriasis and suggest the possi-
bility of epistasis between IL36RN and AP1S3 alleles.
AP1S3 mutations disrupt protein function in keratinocytes
Structural homology modeling indicates that the p.Phe4Cys
change maps to a b-sheet required for protein folding,
whereas the p.Arg33Trp substitution is expected to disrupt the
interaction between AP-1s1C and AP-1m1A (Setta-Kaffetzi
et al., 2014). This strongly suggests that both mutations are
loss-of-function alleles.
To validate these predictions, we first examined the effect
of p.Phe4Cys on the thermal stability of AP-1s1C. After
transfection of wild-type and mutant AP1S3 constructs into
HEK293 cultures, we subjected cell lysates to a temperature
gradient and monitored AP-1s1C levels by western blotting.
We found that p.Phe4Cys proteins were denatured signifi-
cantly more quickly than their wild-type counterparts
(Figure 1b), confirming that the mutation disrupts AP-1s1C
stability.
To investigate the impact of the p.Arg33Trp allele, we
carried out co-immunoprecipitation experiments, using
FLAG-AP1M1 and myc-AP1S3 constructs transfected into
HEK293 cells. As expected, we found that wild-type
myc-AP1s1C co-precipitated with FLAG-AP1m1A. This
interaction, however, was disrupted when FLAG-AP1M1
was co-transfected with a p.Arg33Trp myc-AP1S3 cDNA
(Figure 1c). Similar results were obtained in immunofluores-
cence experiments, showing that wild-type myc-AP1s1C
co-localized with FLAG-AP1m1A, whereas the mutant
p.Arg33Trp protein did not (see Supplementary Figure S1
online). Thus, we concluded that the p.Arg33Trp mutation
disturbs the interaction between AP-1s1C and AP-1m1A, as
predicted in-silico.
Having validated the loss-of-function nature of disease
alleles, we sought to establish which cell types are most
likely to be affected by AP1S3 deficiency. We therefore
measured gene expression in biologically relevant cell pop-
ulations. Although transcript levels were low in neutrophils
and virtually undetectable in CD4þ T lymphocytes, we
observed abundant gene expression in keratinocytes
(Figure 1d). The impact of disease alleles was therefore
modeled in this cell type.
AP1S3 deficiency causes impaired keratinocyte autophagy
Because autophagosome formation requires a functional
AP-1 complex (Guo et al., 2012), we hypothesized that
AP1S3 loss-of-function mutations may disrupt keratinocyte
autophagy.
We first examined this possibility in a HaCaT keratinocyte
cell line stably transduced with a silencing AP1S3 small
hairpin RNA (Setta-Kaffetzi et al., 2014) (Figure 2a). After
inducing autophagy by starvation, we monitored the con-
version of the LC3-I protein into its modified form (LC3-II),
which is a well-recognized autophagosome marker (Klionsky
et al., 2012). We found that LC3-II levels were significantly
reduced in AP1S3 knockdown versus control cell lines
(Figure 2b).
We then repeated the experiment in a HEK293 AP1S3
knockout cell line, generated by clustered regularly inter-
spaced short palindromic repeats (CRISPR)eCRISPR-
associated endonuclease-9 (Cas9) genome editing
(Figure 2c). This confirmed that AP1S3 silencing causes a
very significant decrease in starvation-induced LC3-II accu-
mulation (Figure 2d).
To further validate our findings, we used fluorescence
microscopy to visualize the expression of LC3-green fluo-
rescent protein (GFP) constructs transfected into the HEK293
AP1S3 knockout cell line. We found that the number of
autophagosomes that had incorporated LC3-GFP was signif-
icantly reduced in knockout versus control cells. This
phenotype was rescued by the overexpression of wild-type
but not mutant (p.Arg33Trp) AP1S3 constructs (Figure 2e).
Thus, AP1S3 deficiency disrupts autophagy induction in
multiple experimental systems.
AP1S3 deficiency results in abnormal p62 accumulation and
enhanced Toll-like receptor (TLR) 2/6 signaling
It has been shown that keratinocyte autophagy modulates
NF-kB activation downstream of TLR-2/6 by regulating the
degradation of the p62 adaptor protein (Lee et al., 2011). This
led us to hypothesize that AP1S3 deficiency would cause an
abnormal accumulation of p62, resulting in enhanced NF-kB
signaling. We therefore measured p62 protein levels in
keratinocytes cultured from the hair plucks of one affected
individual (carrying the AP1S3 p.Arg33Trp mutation) and two
healthy control subjects. We found that p62 expression was
markedly increased in the patient’s cells (Figure 3a). A similar
up-regulation was observed in normal primary keratinocytes
transfected with AP1S3 small interfering RNAs (siRNAs)
(Figure 3b and 3c) and in a HaCaT AP1S3 knockout cell line
(see Supplementary Figure S2a and b online). We therefore
Table 1. Clinical phenotype of affected individuals bearing AP1S3 disease alleles
Patient ID Sex Ethnicity Diagnosis Concurrent PV Age of Onset, years IL36RN Genotype AP1S3 Genotype
T010091 F European GPP U 68 p.Ser113Leu/e p.Phe4Cys/e
T030865 F European GPP N <1 p.Ser113Leu/e p.Phe4Cys/e
T016713 F European PPP N 55 e/e p.Arg33Trp/e
T026517 F European PPP N 50 e/e p.Arg33Trp/e
T028754 F European PPP N 49 e/e p.Arg33Trp/e
Abbreviations: F, female; GPP, generalized pustular psoriasis; ID, identifier; N, no; PPP, palmar plantar pustulosis; PV, psoriasis vulgaris; U, unknown.
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concluded that the abnormal p62 accumulation observed in
the patient was a result of AP1S3 deficiency.
To further explore these findings, we measured
macrophage-activating lipopeptide 2 (MALP-2)einduced
cytokine expression in primary keratinocytes transiently
transfected with AP1S3 siRNAs (Figure 3d). Although there
was no IL1B, IL6, or IL8 induction at the examined time
point, we detected a marked increase in TNFA levels. We
also observed a significant induction of IL36A (but not IL36B
or IL36G), a cytokine that drives abnormal immune signaling
in patients with IL36RN mutations (Onoufriadis et al., 2011).
Importantly, the induction of TNFA and IL36A was signifi-
cantly enhanced in AP1S3-deficient cells compared with
control (Figure 3d).
We then repeated the MALP-2 stimulations in the HaCaT
AP1S3 knockout cell line. This confirmed the abnormal
induction of TNFA and IL36A in knockout cells (see
Supplementary Figure S2c).
AP1S3 deficiency causes abnormal IL-1 signaling and
up-regulates baseline IL-36 expression
Autophagy-mediated degradation of p62 also regulates IL-1
signaling (Lee et al., 2012), a response that plays a major
role in autoinflammation. To determine whether AP1S3
deficiency would also affect this pathway, we transfected
primary keratinocytes with AP1S3 siRNA pools and measured
cytokine levels after IL-1 stimulation. Although TNFA
expression was unchanged at the examined time point, we
observed a clear up-regulation of IL1B, IL8, and IL36A tran-
scripts. The induction of all cytokines was markedly up-
regulated in AP1S3-deficient cells compared with control
(Figure 4a). These observations were replicated in HaCaT
AP1S3-knockout cells (see Supplementary Figure S3a online),
thus validating the effects of gene silencing on IL-1 signaling.
Surprisingly, our experiments showed that baseline IL36A
expression was markedly increased in AP1S3-deficient cells,
both at the RNA and protein levels (Figures 4a and b, and see
Supplementary Figure S2c). A similar, although less pro-
nounced, effect was also observed for IL36B and IL36G
mRNA expression (see Supplementary Figures S4a and S4b
online) and IL-8 protein secretion (Figure 4b).
To determine whether this up-regulation was also a
consequence of impaired autophagy, we cultured normal
primary keratinocytes in medium supplemented with
3-methyladenine (3-MA), an agent that blocks the formation
of autophagosomes (Klionsky et al., 2012). As expected, we
found that 3-MA treatment caused an increase in IL-
1edependent cytokine expression. IL36A baseline expression
Figure 2. AP1S3 deficiency results in impaired autophagy. (a) After the generation of a HaCaT AP1S3 knockdown cell line, gene silencing was measured by
real-time PCR, because of cross-reactivity of the anti-AP1s1c antibody with the proteins encoded by AP1S1 and AP1S2. (b) Starvation-induced LC3-II
accumulation was measured by Western blotting and densitometry. The data are presented as mean  standard error of the mean of measurements obtained in
four independent experiments. (c) HEK293 AP1S3 knockout cell lines harboring a c.124delC change (highlighted by a red asterisk in the chromatogram) were
generated by CRISPR/Cas-9 editing. (d) Cells were starved to induce autophagy, and LC3-II accumulation was measured by Western blotting. The data are
presented as described. (e) Control and AP1S3 KO HEK293 cells were transfected with GFP-LC3 and either an empty vector (control and KO panels) or a rescue
construct (wild-type AP1S3 in KO/wt panel and p.Arg33Trp AP1S3 in KO/mut). Starvation-induced LC3 punctae were visualized by confocal fluorescence
microscopy. The data are presented as mean  standard error of the mean of measurements obtained in at least 15 cells per experiment. Scale bar ¼ 5 mm. *P 
0.05, ****P  0.0001. Cas9, CRISPR-associated protein-9; CRISPR, clustered regularly interspaced short palindromic repeats; GFP, green fluorescent protein;
KD, knockdown; KO, knockout; mut, mutated; ns, not significant; wt, wild-type.
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was also up-regulated by 3-MA (Figure 4c). These observa-
tions, which were replicated in HaCaT keratinocytes (see
Supplementary Figure S3b), show that the proinflammatory
effects of AP1S3 deficiency are mediated by a disruption of
keratinocyte autophagy.
Patients harboring AP1S3 mutations up-regulate IL-36
expression and IL-1 signaling
To validate the pathophysiological relevance of our findings,
we cultured keratinocytes from the hair plucks of two
affected individuals (each carrying an AP1S3 mutation and a
wild-type IL36RN sequence) and two healthy control sub-
jects. Although we observed only a weak response to MALP-2
stimulation, we found that cytokine levels were robustly
up-regulated after IL-1 treatment. Importantly, the induction
of IL1B, IL8, and IL36A transcripts was increased in the
keratinocytes of patients compared with control (Figure 5a),
replicating the results generated in AP1S3-knockdown cells.
The basal expression of IL-36 cytokines was also
up-regulated in patient keratinocytes (Figure 5a and b and see
Supplementary Figure S4c), further validating the data
obtained in AP1S3-deficient cells. IL1B and IL8 baseline
transcripts were also significantly overexpressed in the
examined individuals (Figure 5a).
To further investigate the mechanisms underlying these
observations, we measured transcript levels after autophagy
induction by starvation, or blockade, of the IL-36 receptor
with a recombinant antagonist (IL-36Ra). We found that both
treatments could lower patient cytokine expression to the
levels observed in healthy control subjects (Figure 5c, and see
Supplementary Figure S4d). Although the experiment was
carried out in a single patient, the results were also replicated
in AP1S3-knockout cells (see Supplementary Figure S5
online), suggesting that impaired autophagy and enhanced
IL-36 signaling both contribute to the abnormal immune
profile associated with AP1S3 mutations.
DISCUSSION
The aim of our study was to characterize the molecular
mechanisms underlying the cutaneous features of AIDs. We
therefore investigated the pathogenesis of pustular psoriasis,
focusing our attention on AP1S3, a gene that is specifically
mutated in this disease. We first validated the pathogenic
involvement of this locus by demonstrating the presence of
disease alleles in five of the 53 European patients (9.4%) who
were included in our screening. We observed that AP1S3
mutations can be inherited in conjunction with IL36RN
changes, modifying the phenotypic effect of the latter. This
suggests that AP1S3 alleles may exacerbate the effects of
IL36RN deficiency by disturbing IL-36 homeostasis, a notion
that is borne out by the results of our functional studies.
First, our experiments showed that AP1S3 expression was
low or undetectable in cells that do not respond to IL-36
stimulation (neutrophils and CD4þ T cells), whereas tran-
script levels were abundant in keratinocytes, where IL-36
signaling can be activated by TLR agonists (Gabay and
Towne, 2015). The only other known gene for pustular pso-
riasis (CARD14) is also abundantly expressed in keratinocytes
(Berki et al., 2015), suggesting that these cells play an
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important role in cutaneous autoinflammation. This is in
keeping with the emerging view of keratinocytes as immune
sentinels contributing to host defense through the engage-
ment of innate receptors and the production of proin-
flammatory mediators (Di Meglio et al., 2011; Lowes et al.,
2013).
The involvement of AP1S3 in IL-36 regulation is also sup-
ported by repeated observations of increased IL36A expres-
sion in AP1S3-deficient cells and in nonlesional
keratinocytes, derived from patient hair plucks. Of note,
stable AP1S3 knockout also led to constitutive up-regulation
of IL1B and IL8 (see Supplementary Figure S3). Although this
phenotype mirrored the expression profile observed in
patients, it was not replicated in the transient gene-silencing
experiments, where mRNA levels were measured shortly after
knockdown initiation. Although IL36A was up-regulated at
this early time point, the other two cytokines were not,
suggesting that the overexpression of IL1B and IL8 may be
secondary to IL-36 accumulation. Indeed, our experiments
showed that IL-36 receptor blockade is sufficient to
normalize IL1B and IL8 levels in patient keratinocytes.
Thus, our observations place IL-36 at the center of a
proinflammatory loop that drives enhanced cytokine pro-
duction in skin autoinflammation (see Supplementary
Figure S6 online). This is in keeping with the results of
recent studies, indicating that IL36A is markedly up-regulated
in psoriatic skin and that this is unlikely to be a secondary
consequence of inflammation (Swindell et al., 2016). Given
that therapeutics blocking IL-36 are now under development
(Wolf and Ferris, 2014), these discoveries have important
translational implications.
Our experiments show that the effects of AP1S3 mutations
on cytokine production are mediated by disruption of
keratinocyte autophagy, causing abnormal p62 accumulation
and enhanced NF-kB activation downstream of TLR-2/6 and
IL-1R. Of note, p62 transcripts are up-regulated in psoriatic
lesions, whereas the expression of molecules that contribute
to skin inflammation is reduced in p62-deficient keratino-
cytes (Lee et al., 2011).
Here, IL-1 treatment of patient cells (which overexpress
p62) caused a moderate (w2-fold) induction of IL1B
transcripts (Figure 5) but a substantial up-regulation of IL8
(>20-fold). Given that the latter cytokine plays a fundamental
role in driving neutrophilic skin infiltration, this finding has a
clear pathological relevance.
Autophagy can also modulate cytokine production at the
posttranslational level, by degrading components of the
inflammasome, the molecular complex that cleaves pro-IL1b
into a bioactive molecule (Shi et al., 2012). Although this
process has been chiefly investigated in mouse macrophages,
it might also be active in human keratinocytes, where it could
amplify the effects of AP1S3 mutations.
It is now widely accepted that perturbations of protein
degradation play a pathogenic role in various AIDs with
prominent dermatological features (Martinon and
Aksentijevich, 2015). Evidence recently generated in
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results obtained in two independent experiments and are presented as mean  standard error of the mean of (a) duplicate or (b, c) triplicate measurements.
*P  0.05, **P  0.01. 3-MA, 3-methyladenine; siRNA, small interfering RNA.
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animal models also indicates that therapeutic effects of
anakinra (an IL-1 blocker widely used for the treatment of
AIDs) are partly mediated by the rescue of defective auto-
phagy (Iannitti et al., 2016). In the light of this evidence, our
work warrants further studies of impaired keratinocyte auto-
phagy as a pathogenic mechanism and therapeutic target in
skin autoinflammation.
METHODS
Participants
This study was performed in accordance with the declaration of
Helsinki and was approved by the ethics committees of participating
institutions. Written informed consent was obtained from all
participants. Patients were ascertained by trained dermatologists (see
Supplementary Table S3 online) on the basis of established diag-
nostic criteria (Griffiths and Barker, 2010). Patients 1 and 2 were
described elsewhere as T002206 and T001882, respectively (Setta-
Kaffetzi et al., 2014). Healthy volunteers were recruited within
King’s College London. All affected individuals were screened for
IL36RN and AP1S3 mutations as described (Onoufriadis et al., 2011;
Setta-Kaffetzi et al., 2014).
Plasmids and constructs
Thewild-type andmutant myc-tagged AP1S3 constructs are described
elsewhere (Setta-Kaffetzi et al., 2014). The FLAG-AP1M1constructwas
generated by cloning the gene coding sequence into a c-Flag pcDNA3
vector (Addgene #20011). CRISPR/Cas9 guide RNAs (see
Supplementary Table S4 online)were designedwith theCRISPR design
tool (http://crispr.mit.edu/) and cloned into a pSpCas9BB-2A-GFP
vector (Addgene #48138), as described elsewhere (Ran et al., 2013).
All constructs were validated by Sanger sequencing.
Primary cell culture
Primary keratinocytes and dermal fibroblasts were isolated from
healthy skin discarded after plastic surgery. The keratinocytes were
maintained in Epilife keratinocyte medium supplemented with Sup-
plement 7 and 1% penicillin-streptomycin, and the fibroblasts were
grown in DMEM supplemented with 10% fetal bovine serum and 1%
penicillin-streptomycin (all reagents from Gibco, Waltham, MA).
Keratinocytes were derived from hair plucks as described else-
where (Aasen and Izpisua Belmonte, 2010). Briefly, 12 hairs were
plucked from the temporal scalp and placed in mTeSR1 medium
(Stem Cell Technologies, Vancouver, Canada) containing 1%
penicillin-streptomycin and 250 ng/ml amphotericin B (Sigma, St.
Louis, MO). Once outgrowths were visible, mTeSR1 was replaced
with Epilife keratinocyte medium containing Supplement 7 and 1%
penicillin-streptomycin. After 14 days, cells were stimulated.
Thermal stability assay
HEK293 cells were transfected with the indicated constructs, using
Lipofectamine 2000 (Life Technologies, Waltham, MA). Cell lysates
were then incubated for 5 minutes across a 37e57 C temperature
gradient. Samples were centrifuged for 30 minutes at 13,000 rpm at
4 C, and the soluble fraction (supernatant) was analyzed by
Western blotting.
CRISPR/Cas9 genome editing
The protocol described by Ran et al. (2013) was used to edit HaCaT
and HEK293 cells maintained in complete DMEM. Briefly, the guide
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Figure 5. Abnormal cytokine expression in the keratinocytes of patients harboring AP1S3mutations. (a) Primary keratinocytes were stimulated with IL-1b, and
cytokine induction was measured by real-time PCR. The data are presented as mean  standard error of the mean of duplicate stimulations carried out in the
cells of two unrelated patients and two healthy control subjects. (b) IL-36a and IL-8 production was measured in culture supernatants by ELISA. Data are
presented as mean  standard error of the mean of triplicate measurements. (c) Primary keratinocytes were starved to induce autophagy or cultured in the
presence of IL-36Ra. Gene expression was measured by real-time PCR. The data are presented as mean  standard error of the mean of triplicate measurements,
obtained in one patient and two healthy control subjects. *P < 0.05, **P < 0.01, ***P < 0.001. ns, not significant.
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RNA construct was transfected into the cells, using Lipofectamine
2000. After 48 hours, GFP-positive cells were isolated by flow
cytometry and seeded for clonal expansion. The resulting cell lines
were validated by Sanger sequencing of the target region, paralo-
gous loci, and off-target sites predicted by the CRISPR design tool.
The expression of AP1S1, AP1S2, and AP1S3 was also measured by
real-time PCR. Control cells were transfected with an empty
pSpCas9BB-2A-GFP vector.
Cell stimulation
For autophagy induction, cells were starved for 18 hours in
Hank’s Balanced Salt solution (Gibco), and protein extracts were
analyzed by Western blotting. For autophagy inhibition, cells were
pretreated with 10mmol/L of 3-MA (Sigma) for 5 hours and then
stimulated with 20ng/ml of IL-1b (Sigma) for 2 hours, in the presence
3-MA.
Alternatively, primary or immortalized keratinocytes were treated
with 100ng/ml of MALP2 (Bio-techne, Minneapolis, MN) for 42
hours, 20ng/ml of IL-1b for 2 hours, 100ng/ml of IL-36Ra
(Bio-techne) for 5 hours or were starved as described.
For transient gene-silencing experiments, cells were transfected
for 48 hours with 33 nmol/L of AP1S3ON-TARGET plus SMARTpool
siRNA or ON-TARGETplus nontargeting siRNA (GE Dharmacon,
Lafayette, CO) using Lipofectamine 2000 and stimulated as
described above.
Real-time PCR and ELISA
RNAs isolated from skin, lymphocytes, in vitro derived macro-
phages/dendritic cells, and neutrophils were provided by Frank
Nestle, Susan John, Leonie Taams (King’s College London), and
Benjamin Fairfax (Wellcome Trust Centre for Human Genetics,
Oxford), respectively. All remaining RNAs were isolated using the
RNeasy Mini Plus kit (Qiagen, Hilden, Germany). Gene expression
was assessed by real-time PCR by using the primers listed in
Supplementary Table S4 online. Transcript levels were normalized to
PPIA or B2M expression, measured with Applied Biosystems (Foster
City, CA) TaqMan probes. IL-36a and IL-8 production was measured
with the Human IL36A ELISA Kit (Sigma) and Human IL-8 ELISA Kit
(Sigma).
Co-immunoprecipitation and Western blotting
A rabbit monoclonal anti-FLAG (1:50, Cell Signaling Technology,
Danvers, MA) was used in co-immunoprecipitation experiments,
whereas Western blots were probed with rabbit polyclonal anti-LC3
(Cell Signaling Technology), rabbit polyclonal anti-b actin (Cell
Signaling Technology), rabbit polyclonal anti-p62 (Sigma), or mouse
monoclonal anti-myc (Thermo Scientific, Waltham, MA) (all
1:1,000). Densitometry was undertaken with Image J software
(Schneider et al., 2012).
Immunofluorescence microscopy
In the co-localization experiments, HEK293 cells were co-
transfected with the indicated constructs, using Lipofectamine
2000. After 24 hours, cells were fixed and incubated with 1:500
mouse monoclonal anti-myc (Cell Signaling Technology) and 1:600
rabbit monoclonal anti-FLAG. Slides were imaged by using a C2
confocal microscope (Nikon, Tokyo, Japan), and z-stack images of at
least 15 cells per slide were taken.
In autophagy induction experiments, HEK293 cells were trans-
fected with a pEGFP-LC3 plasmid (Addgene #24920) and the indi-
cated construct, using Lipofectamine 2000. After 24 hours, cells
were starved for 18 hours in Hank’s Balanced Salt solution
supplemented with 0.1 mmol/L of Bafilomycin A1 (Sigma). Cells
were imaged as described above and autophagosomes were counted
by using NIS-Elements Advanced Research software (Nikon).
Statistics
Means were compared with unpaired Student t tests. Error bars
represent standard error of the mean.
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